Hyperscale Data held about $18.5 million in Bitcoin and $37.5 million in cash as of late September, totaling $56 million in assets, which is 153% of its market cap. The company stopped Bitcoin mining at its Michigan facility on September 1 to convert it into an AI data center under a 10-year customer agreement with options to extend. This shift supports a revenue projection exceeding $1.2 billion if options are exercised. Hyperscale also plans to spin off its mining operations into a new entity, Patriot BTC, though this separation is not yet finalized.
Hyperscale Data's pivot from Bitcoin mining to AI data centers provides context for cryptocurrency market activity. For readers following major cryptocurrencies on Pluang, here is the market snapshot as of Oct 06, 2026 17:44 WIB: out of 50 priced cryptocurrencies, 15 rose and 33 fell today. Notable movers include BAL (Balancer) at Rp16.297 with a 1-day change of +11.14%, SAND (The Sandbox) at Rp1.188 down -9.22%, and FIL (Filecoin) at Rp20.790 up +8.22%.
Over the past six months, Costco's stock has fallen by 10%, contrasting with the S&P 500's 17% gain. This decline has sparked debate on whether Costco's shares, now trading under $900, represent a buying opportunity. Investors are weighing if the pri...
Elon Musk has confirmed that his company is in discussions with Terafab, marking a potential new chip manufacturing partner alongside Intel, which has been the only named chip partner until now. This development could diversify the supply chain and e...
SpaceX stock surged over 17% recently, trading near $173.30 as of October 6, 2026. Goldman Sachs raised its 12-month price target to $230, expecting a 32.7% upside driven by strong AI segment growth and expanding space opportunities. Morgan Stanley a...
Barrick Gold resolved its dispute with Newmont, receiving a $1.95 billion payment and approval to list its North American gold assets separately. This move aims to unlock hidden value, particularly in Nevada, while leaving African and copper assets o...
Viking Therapeutics has launched Part 2 of a study exploring oral and subcutaneous dosing regimens of VK2735, a dual GLP-1/GIP receptor agonist, to maintain weight loss in adults with obesity. This randomized, placebo-controlled trial follows positiv...
